AcelRx Pharma (ACRX) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to AcelRx Pharma (ACRX) Tops Q4 EPS by 3c

AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results

March 2, 2017 4:01 PM EST

REDWOOD CITY, Calif., March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2016.

Corporate and Clinical HighlightsDuring the fourth quarter of 2016, AcelRx submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S. Food and Drug Administration (FDA) for DSUVIA (sufentanil sublingual tablet, 30 mcg) for the treatment of patients experiencing moderate-to-severe... More